-
Mashup Score: 19
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade
Source: www.fda.govCategories: General Medicine NewsTweet
-
Mashup Score: 4FDA/The Osteosarcoma Institute (OSI) Workshop - 14 day(s) ago
Meeting information for FDA/The Osteosarcoma Institute (OSI) Workshop
Source: www.fda.govCategories: General Medicine NewsTweet-
🚨 Oct 10, 2025: FDA & @OSInstitute workshop on advancing #osteosarcoma drug development. 📍 Washington DC + Virtual ⏰ 9:30am-5pm ET 🎯 Connecting research & regulatory pathways Register by Sept 24 for in-person attendance: https://t.co/PLwPDgOvzK #CancerResearch https://t.co/DuaeeUfQcN
-
-
Mashup Score: 16
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade
Source: www.fda.govCategories: General Medicine NewsTweet-
FDA approves a treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. https://t.co/BUvS5FGsEo https://t.co/zdT7kYrsHy
-
-
Mashup Score: 3Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better - PubMed - 25 day(s) ago
Despite survival gains for many pediatric cancers since the 1970s, cancer remains the leading cause of death by disease for children and adolescents in the United States. Survivors of pediatric cancer often experience acute and long-term toxicities resulting in diminished quality of life and reduced …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine NewsTweet-
FDA article clarifies perspectives on dosage optimization in pediatric oncology and affirms our commitment to expedite development of more effective, better tolerated drugs and biologics for pediatric cancer patients. @CCR_AACR https://t.co/FUjejx18XN
-
-
Mashup Score: 15FDA approves darolutamide - 26 day(s) ago
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide.
Source: www.fda.govCategories: General Medicine NewsTweet-
FDA approves a treatment for metastatic castration-sensitive prostate cancer. https://t.co/DB6uVtFUBa https://t.co/a3l61UrsMr
-
-
Mashup Score: 15FDA approves darolutamide - 26 day(s) ago
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide.
Source: www.fda.govCategories: General Medicine NewsTweet-
FDA approves a treatment for metastatic castration-sensitive prostate cancer. https://t.co/DB6uVtFUBa https://t.co/a3l61UrsMr
-
-
Mashup Score: 15FDA approves darolutamide - 27 day(s) ago
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide.
Source: www.fda.govCategories: General Medicine NewsTweet-
FDA approves a treatment for metastatic castration-sensitive prostate cancer. https://t.co/DB6uVtFUBa https://t.co/a3l61UrsMr
-
-
Mashup Score: 2FDA approves darolutamide - 27 day(s) ago
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide.
Source: www.fda.govCategories: General Medicine NewsTweet-
FDA approves a treatment for metastatic castration-sensitive prostate cancer. https://t.co/DB6uVtFUBa https://t.co/a3l61UrsMr
-
-
Mashup Score: 12Artificial Intelligence and Machine Learning Innovations to Improve Design and Representativeness in Oncology Clinical Trials - 28 day(s) ago
The integration of artificial intelligence (AI) and machine learning (ML) in oncology clinical trials is rapidly evolving alongside the broader field. For example, AI-driven adaptive trial designs may allow for real-time modifications based on emerging …We review use of artificial intelligence-based technologies in oncology clinical trials, with potential to improve patient recruitment and stratification, trial design and operations, and data management.
Source: ascopubs.orgCategories: General Medicine NewsTweet-
A review of #AI and #machinelearning in oncology clinical trials highlights the potential to improve patient recruitment and stratification, trial design and operations, and data management. #ASCO2025 Read more: https://t.co/rsWB7BN8oU #CancerResearch #ClinicalTrials https://t.co/207XYI7DQN
-
-
Mashup Score: 6Program Guide – ASCO Meeting Program Guide - 29 day(s) ago
Jennifer Gao Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD Jennifer Gao, Joyce Cheng, Mallorie Fiero, Shenghui Tang, Suparna Wedam, Melanie Royce, Tatiana Prowell, Elaine Chang, Mirat Shah, Preeti Narayan, Christy Osgood, Nicole Gormley, Tamy Kim, Richard Pazdur, Paul Kluetz, Laleh Amiri-Kordestani Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver
Source: meetings.asco.orgCategories: General Medicine NewsTweet-
Large novel FDA analysis suggests adding a CDKI to aromatase inhibitor therapy improved overall survival in patients with HR-positive, HER2-negative advanced or metastatic breast cancer. #ASCO25 https://t.co/t8K8rU7svR https://t.co/us3QYhJJXu
-
FDA approves a treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. https://t.co/BUvS5FGsEo https://t.co/zdT7kYrsHy